Immunological and clinical consequences of Tysabri

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Immunological and clinical consequences of Tysabri

Postby MSUK » Mon Sep 19, 2011 11:58 pm

Immunological and clinical consequences of treating a patient with natalizumab

Image


Abstract

Background: Long-term therapy with natalizumab increases the risk of progressive multifocal leukoencephalopathy (PML).

Objectives: We present a patient study through therapy, the diagnosis of PML (after 29 infusions), plasma exchange (PE) and development of immune reconstitution inflammatory syndrome (IRIS).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2211
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Re: Immunological and clinical consequences of Tysabri

Postby NHE » Tue Sep 20, 2011 1:54 am

Additional info from the abstract...
With no clinical, routine laboratory or cerebrospinal fluid (CSF) changes, MRI 2 months after PE demonstrated progressive lesion development. Brain histopathology confirmed the presence of infiltrates indicative of IRIS without clinical signs, immunologically accompanied by CCR7/CCR5 recovery of peripheral monocytes.

Conclusion: Natalizumab-associated immunological changes accompanying PML were reversible after PE; IRIS can occur very late, remain asymptomatic and be elusive to CSF analysis.


NHE
User avatar
NHE
Volunteer Moderator
 
Posts: 3391
Joined: Sat Nov 20, 2004 3:00 pm


Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service